Home › Funds › Merck & Co., Inc. › XLO
Merck & Co., Inc. position in XLO
XILIO THERAPEUTICS INC · Health Care
Merck & Co., Inc. reported holding 105,982 shares of XLO (XILIO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$959K, representing 0.12% of its reported portfolio and ranking #11 among its reported holdings. Merck & Co., Inc. has disclosed XLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s XLO position evolved
Merck & Co., Inc. first disclosed a stake in XLO in Q4 2024 at 1,483,758 shares (US$1.4M). Across 8 filings, Merck & Co., Inc. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 105,982 shares valued at US$959K. Notable position changes include a 93% trim in Q1 2026 (shares rose 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.48M | $1.42M | New |
| Q1 2025 | 1.48M | $1.07M | Hold |
| Q2 2025 | 1.48M | $1.01M | Hold |
| Q3 2025 | 1.48M | $1.25M | Hold |
| Q4 2025 | 1.48M | $949.90K | Hold |
| Q1 2026 | 105.98K | $891.31K | Reduce |
| Q2 2026 | 105.98K | $1.02M | Hold |
| Q3 2026 | 105.98K | $959.14K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XLO and 13F data
XLO (XILIO THERAPEUTICS INC) is a Health Care company. 26 other funds we track also report a position in XLO — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$6.4M), GILEAD SCIENCES, INC. (US$5.9M), Frazier Life Sciences Management, L.P. (US$4.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XLO
- Bain Capital Life Sciences Investors, LLC 664.02K sh · $6.36M · Q2 2026
- GILEAD SCIENCES, INC. 650.39K sh · $5.89M · Q3 2026
- Frazier Life Sciences Management, L.P. 422.50K sh · $4.05M · Q2 2026
- Stonepine Capital Management, LLC 189.09K sh · $1.71M · Q3 2026
- Sio Capital Management, LLC 152.46K sh · $1.46M · Q2 2026
- AJU IB Investment Co., Ltd. 47.70K sh · $401.12K · Q1 2026
- Velan Capital Investment Management LP 14.29K sh · $136.85K · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held XLO?
Merck & Co., Inc. has disclosed XLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Merck & Co., Inc.'s current position in XLO?
As of Q3 2026, Merck & Co., Inc. holds 105.98K shares of XLO (XILIO THERAPEUTICS INC), valued at $959.14K, representing 0.12% of its reported portfolio and ranking #11.
Has Merck & Co., Inc. been buying or selling XLO?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in XLO.
Which other funds hold XLO?
Other major institutional holders of XLO include Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., Frazier Life Sciences Management, L.P., among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.